Skip to NavigationSkip to content

british nhs

UK cancer survival lagging behind other nations

Cancer survival in the UK is falling behind other high-income nations, despite seeing an overall improvement in survival rates, according to a study published in Lancet Oncology.

Advances in treatment and surgical techniques are thought to behind the UK’s progress, as five-year survival rates for rectal and colon cancer improved the most since 1995, while pancreatic cancer improved the least.

Celgene threatens to scale back UK clinical trial investment after CDF snub

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the UK, as it cannot justify the expenditure in the face of cuts to the Cancer Drugs Fund.

Two of Celgene’s treatments for multiple myeloma, Revlimid (lenalidomide) and Imnovid (pomalidomide), and its pancreatic cancer treatment Abraxane (nab-paclitaxel), have been de-listed from the CDF in the latest round of funding cuts by NHS England.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches